Role of Angiogenesis Inhibitors in Cancer
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: closed (31 December 2019) | Viewed by 3284
Special Issue Editor
Special Issue Information
Dear Colleagues,
Tumor angiogenesis is important for cancer progression. Hence, anti-angiogenic therapies have been developed and used to treat millions of cancer patients. Almost all clinically approved anti-angiogenic drugs block VEGF signaling. However, several reports have shed light on resistance, adaptation, insufficient efficacy and toxicity, which limit the success in human cancers. Mechanisms of resistance and adaptation have been extensively explored and indicate several cellular and molecular mechanisms that compensate the inhibition of VEGF pathways. The crosstalk between oncogenic signaling and tumor-associated stroma cells provides a strong rationale for combining angiogenesis inhibitors with targeted anticancer agents. A combination of angiogenesis and immune checkpoint inhibitors is ongoing in clinical trials and preclinical studies have found that this combination is beneficial. Emerging evidence has brought about a paradigm shift in understanding the mechanisms of angiogenesis by demonstrating that the activation of metabolic pathways orchestrates endothelial cell proliferation and vessel sprouting.
In this Special Issue, we welcome contributions of research or review articles on the improvement of anti-angiogenic therapies in cancer.
Dr. Nor Eddine Sounni
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Anti-angiogenic therapies
- Resistance
- Cancer progression
- Metabolism
- Immune checkpoint inhibitors
